Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurol Clin. 2013 Aug;31(3):869-78. doi: 10.1016/j.ncl.2013.03.012. Epub 2013 May 18.

Immunotherapy for Alzheimer's disease.

Author information

1
Department of Neurology, Indiana University School of Medicine, 355 West 16th Street, Suite 4700, Indianapolis, IN 46202, USA. mfarlow@iupui.edu

Abstract

The immune system plays a significant role in Alzheimer disease (AD). β-Amyloid deposition in the cortex is thought to be an initiating event in AD and the widely believed amyloid hypothesis proposes removal of amyloid may delay disease progression. Human trials of active or passive immune agents have failed to show benefit and increased adverse events of vasogenic edema and microhemorrhages. Evidence suggests the illness may be too advanced by the time patients are symptomatic with dementia. Future directions include better understanding of how and where immunotherapies should be targeted and treating patients at earlier stages of the illness.

KEYWORDS:

Alzheimer disease; Immunotherapy; β-amyloid

PMID:
23896510
DOI:
10.1016/j.ncl.2013.03.012
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center